W. Krzyzanski

发表

Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells

R. Ramakrishnan, W. Jusko, W. Krzyzanski, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Mathematical Formalism for the Properties of Four Basic Models of Indirect Pharmacodynamic Responses

W. Jusko, W. Krzyzanski, 1997, Journal of Pharmacokinetics and Biopharmaceutics.

Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action

W. Jusko, J. Pérez-Ruixo, A. Chow, 2005, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

W. Jusko, W. Krzyzanski, W. Cheung, 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects

J. Pérez-Ruixo, W. Krzyzanski, 2007, Pharmaceutical Research.

Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats

W. Jusko, S. Woo, W. Krzyzanski, 2006, Journal of Pharmacology and Experimental Therapeutics.

Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells

J. Pérez-Ruixo, A. Vermeulen, W. Krzyzanski, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Dynamics of Erythropoietic Markers in Response to Hypoxia in Rats

W. Krzyzanski, Ying Zhang, I. Singh, 2014 .

Population Model of Serum Creatinine as Time-Dependent Covariate in Neonates

J. N. van den Anker, A. Smits, K. Allegaert, 2021, The AAPS Journal.

Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals

Yow-Ming C Wang, J. Pérez-Ruixo, A. Chow, 2013, Pharmaceutical Research.

Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects

J. Pérez-Ruixo, Honghui Zhou, A. Cohen, 2009, Clinical pharmacokinetics.

Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor

W. Krzyzanski, Xiaoyu Yan, Yang Chen, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575

M. Fink, W. Krzyzanski, P. Lowe, 2012, Journal of clinical pharmacology.

Lifespan based indirect response models

J. P. Perez Ruixo, W. Krzyzanski, J. P. Pérez Ruixo, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys

Yow-Ming C Wang, J. Pérez-Ruixo, Yuling Wu, 2010, The AAPS Journal.

Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)

W. Jusko, S. Woo, W. Krzyzanski, 2007, Journal of Pharmacokinetics and Pharmacodynamics.

Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

D. Mager, W. Krzyzanski, 2005, Pharmaceutical Research.

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach

M. Panesar, L. M. Nguyen, W. Krzyzanski, 2020, CPT: pharmacometrics & systems pharmacology.

Neuronal integrative analysis of the "Dumbbell" model for passive neurons.

R. R. Poznanski, J. Bell, W. Krzyzanski, 2002, Journal of integrative neuroscience.

Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models

W. Krzyzanski, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes

W. Krzyzanski, I. Singh, E. Nagiec, 2015, CPT: pharmacometrics & systems pharmacology.

Pharmacodynamic models of age-structured cell populations

W. Krzyzanski, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.

R. Straubinger, W. Krzyzanski, J. Qu, 2007, Anticancer research.

Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations

J. Schropp, J. Pérez-Ruixo, G. Koch, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers

W. Jusko, S. Woo, W. Krzyzanski, 2008, Journal of clinical pharmacology.

Pharmacodynamics of CNTO 530 and Darbepoetin-α in Human TNF-α Transgenic Mice, a Murine Model of Anemia of Chronic Disease

P. Bugelski, W. Krzyzanski, D. Makropoulos, 2011 .

Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats

Aman P. Singh, P. Wiczling, L. M. Nguyen, 2018, Front. Pharmacol..

Erythropoietin-Induced Erythroid Precursor Pool Depletion Causes Erythropoietin Hyporesponsiveness

S. Ait-Oudhia, W. Krzyzanski, Xiaoyu Yan, 2013, Pharmaceutical Research.

Dynamics of Erythroferrone Response to Erythropoietin in Rats

R. Wong, W. Krzyzanski, Xiaoyu Yan, 2022, Frontiers in Pharmacology.

vRNA structured population model for Hepatitis C Virus dynamics.

F. De Ridder, A. Vermeulen, W. Krzyzanski, 2015, Journal of theoretical biology.

Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys

J. Pérez-Ruixo, B. Sasu, W. Krzyzanski, 2016, The AAPS Journal.

Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial

W. Jusko, W. Krzyzanski, Tianjing Ren, 2022, Journal of Pharmacokinetics and Pharmacodynamics.

Non‐linear mixed effect modeling of the time‐variant disposition of erythropoietin in anemic cancer patients

S. Ait-Oudhia, A. Vermeulen, W. Krzyzanski, 2011, Biopharmaceutics & drug disposition.

Note: Caution in Use of Empirical Equations for Pharmacodynamic Indirect Response Models

W. Jusko, W. Krzyzanski, 1998, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetic model of target-mediated disposition of thrombopoietin

W. Krzyzanski, F. Jin, 2004, AAPS PharmSci.

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition

M. Sternlicht, W. Krzyzanski, K. Lipson, 2016, Pharmaceutical Research.

Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B

W. Krzyzanski, G. Rao, 2017, PloS one.

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents

W. Krzyzanski, X. Yan, 2013, CPT: pharmacometrics & systems pharmacology.

A cell-level model of pharmacodynamics-mediated drug disposition

J. Pérez-Ruixo, J. Harrold, W. Krzyzanski, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women

W. Jusko, R. Bies, A. Jobe, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamic models of age-structured cell populations

W. Krzyzanski, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

D-optimal designs for parameter estimation for indirect pharmacodynamic response models

W. Jusko, W. Greco, W. Krzyzanski, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

D‐optimal designs for parameter estimation for indirect pharmacodynamic response models

W. Jusko, W. Greco, W. Krzyzanski, 2003 .

Indirect pharmacodynamic models for responses with circadian removal

W. Jusko, Vivaswath S. Ayyar, W. Krzyzanski, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations

J. Schropp, J. Pérez-Ruixo, G. Koch, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor

W. Krzyzanski, Xiaoyu Yan, Yang Chen, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans

Wojciech Krzyzanski, William J Jusko, Sukyung Woo, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

J. Pérez-Ruixo, S. Elliott, A. Chow, 2013, Clinical Pharmacokinetics.

Evaluation of Epoetin Alpha (rHuEPO) and Darbepoetin Alpha (DARB) on Human Burst-colony Formation (BFU-E) in Culture

W. Krzyzanski, H. Messner, C. Lau, 2006, The Journal of international medical research.

Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics

Frank Gibbons, Wojciech Krzyzanski, F. Gibbons, 2014, PloS one.

Use of a Local Sensitivity Analysis to Inform Study Design Based on a Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid

M. Morris, Bridget L. Morse, W. Krzyzanski, 2011, The AAPS Journal.

Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice

J. Pérez-Ruixo, J. Harrold, W. Krzyzanski, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

D. Mager, W. Krzyzanski, Xiaoyu Yan, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

Dose Correction for a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens

W. Krzyzanski, Xiaoyu Yan, J. P. Ruixo, 2020, The AAPS Journal.

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition

M. Sternlicht, W. Krzyzanski, K. Lipson, 2016, Pharmaceutical Research.

Dose correction for the Michaelis–Menten approximation of the target-mediated drug disposition model

W. Krzyzanski, Xiaoyu Yan, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations

Wojciech Krzyzanski, Etienne Pigeolet, Martin Fink, 2010, Journal of clinical pharmacology.

Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model

D. Mager, W. Krzyzanski, Anshu Marathe, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition

Wojciech Krzyzanski, Donald E. Mager, Anson K. Abraham, 2007, The AAPS Journal.

A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats.

Wojciech Krzyzanski, Itay Perlstein, A. Hoffman, 2002, Journal of pharmaceutical sciences.

Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients

P. Wiczling, T. Małkiewicz, Z. Kokot, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

Yow-Ming C Wang, J. Pérez-Ruixo, A. Chow, 2010, The AAPS Journal.

Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats

S. Ait-Oudhia, W. Krzyzanski, J. Scherrmann, 2010, Journal of Pharmacology and Experimental Therapeutics.

Time‐dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats

S. Ait-Oudhia, W. Krzyzanski, J. Scherrmann, 2010, Biopharmaceutics & drug disposition.

The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats

R. Kaliszan, P. Wiczling, W. Krzyzanski, 2014, Biopharmaceutics & drug disposition.

Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats

S. Ait-Oudhia, P. Wiczling, W. Krzyzanski, 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia

Dongyang Liu, R. Wong, W. Krzyzanski, 2023, Pharmaceutics.

Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals

Yow-Ming C Wang, J. Pérez-Ruixo, A. Chow, 2013, Pharmaceutical Research.

Lifespan based indirect response models

J. P. Perez Ruixo, W. Krzyzanski, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects

J. Pérez-Ruixo, W. Krzyzanski, J. Hing, 2008, Clinical pharmacokinetics.

A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats

L. M. Nguyen, W. Krzyzanski, Xiaoyu Yan, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys

J. Pérez-Ruixo, B. Sasu, W. Krzyzanski, 2016, The AAPS Journal.

Pharmacodynamic Modeling of Lansoprazole Using an Indirect Irreversible Response Model

W. Jusko, W. Krzyzanski, T. Puchalski, 2001, Journal of clinical pharmacology.

ALGORITHM FOR APPLICATION OF FOURIER ANALYSIS FOR BIORHYTHMIC BASELINES OF PHARMACODYNAMIC INDIRECT RESPONSE MODELS

W. Jusko, W. Krzyzanski, Abhijit Chakraborty, 2000, Chronobiology international.

Multiple-Pool Cell Lifespan Model of Hematologic Effects of Anticancer Agents

W. Jusko, W. Krzyzanski, 2002, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamic model for chemotherapy-induced anemia in rats

W. Jusko, S. Woo, W. Krzyzanski, 2008, Cancer Chemotherapy and Pharmacology.

Asymptotics of the total net direct pharmacological effect for large drug doses

W. Krzyzanski, 2000, Journal of mathematical biology.

Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations

Wojciech Krzyzanski, Etienne Pigeolet, Frank Lüdicke, 2009, Clinical pharmacokinetics.

Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells.

R. Rabin, W. Krzyzanski, Jan Oberdoester, 2007, Life sciences.

Influence of Haloperidol and Clozapine on Some Behavioral Effects in Rats

K. Kus, W. Krzyzanski, E. Nowakowska, 2006, Arzneimittelforschung.

Flow cytometric assessment of homeostatic aging of reticulocytes in rats.

P. Wiczling, W. Krzyzanski, 2008, Experimental hematology.

Method of determination of the reticulocyte age distribution from flow cytometry count by a structured‐population model

P. Wiczling, W. Krzyzanski, 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Erythropoietin-Induced Erythroid Precursor Pool Depletion Causes Erythropoietin Hyporesponsiveness

S. Ait-Oudhia, W. Krzyzanski, Xiaoyu Yan, 2013, Pharmaceutical Research.

Reticulocyte-based estimation of red blood cell lifespan.

M. Brier, A. Gaweda, W. Krzyzanski, 2013, Experimental hematology.

Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

Wojciech Krzyzanski, W. Krzyzanski, E. Wyska, 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

Definition and Validation of a Novel Metric of Erythropoiesis‐Stimulating Agent Response in Hemodialysis Patients

M. Panesar, W. Krzyzanski, A. Forrest, 2019, Journal of clinical pharmacology.

Direct, Indirect, and Signal Transduction Response Modeling

Wojciech Krzyzanski, W. Krzyzanski, 2016 .

Mathematical Modeling of Circadian Cortisol Concentrations Using Indirect Response Models: Comparison of Several Methods

Wojciech Krzyzanski, William J. Jusko, W. Jusko, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition

Aman P. Singh, Anson K. Abraham, Steven W. Martin, 2015, The AAPS Journal.

Application of Moment Analysis to the Sigmoid Effect Model for Drug Administered Intravenously

W. Jusko, W. Krzyzanski, 1997, Pharmaceutical Research.

Assessment of Basic Indirect Pharmacodynamic Response Models with Physiological Limits

W. Jusko, W. Krzyzanski, Zhenling Yao, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition

Wojciech Krzyzanski, William J. Jusko, W. Jusko, 2001, Journal of Pharmacokinetics and Pharmacodynamics.

Analysis of a model of membrane potential for a skin receptor.

J. Bell, W. Krzyzanski, 1999, Mathematical biosciences.

Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models

Wojciech Krzyzanski, William J. Jusko, Justin C. Earp, 2004, Journal of Pharmacokinetics and Pharmacodynamics.

Integrated functions for four basic models of indirect pharmacodynamic response.

W J Jusko, W. Jusko, W. Krzyzanski, 1998, Journal of pharmaceutical sciences.

Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies

W. Krzyzanski, P. Lowe, M. Elmeliegy, 2014, The AAPS Journal.

Special issue: chronopharmacometrics

W. Krzyzanski, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Oral Delivery and Pharmacokinetic Models

W. Krzyzanski, 2021, Drug Delivery Approaches.

Special issue: mathematical pharmacology

Wojciech Krzyzanski, J G Coen van Hasselt, W. Krzyzanski, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life

A. Gaedigk, J. Leeder, W. Krzyzanski, 2022, CPT: pharmacometrics & systems pharmacology.

Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids

W. Jusko, A. Jobe, M. Milad, 2023, CPT: pharmacometrics & systems pharmacology.

Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women

W. Jusko, R. Bies, A. Jobe, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women

W. Jusko, R. Bies, A. Jobe, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates

K. Allegaert, A. Vermeulen, W. Krzyzanski, 2019, The AAPS Journal.

Delay differential equations based models in NONMEM

J. Schropp, J. P. Perez Ruixo, G. Koch, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Solving delay differential equations in S-ADAPT by method of steps

Robert J. Bauer, Wojciech Krzyzanski, Gary Mo, 2013, Comput. Methods Programs Biomed..

Systems Pharmacology Models for Guiding Drug Design

W. Krzyzanski, 2013, CPT: Pharmacometrics & Systems Pharmacology.

Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition

Aman P. Singh, Anson K. Abraham, Steven W. Martin, 2014, The AAPS Journal.

Ordinary differential equation approximation of gamma distributed delay model

W. Krzyzanski, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression

Shuhua Hu, W. Krzyzanski, Mike Dunlavey, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamic Modeling of Thrombopoietin, Platelet, and Megakaryocyte Dynamics in Patients with Acute Myeloid Leukemia Undergoing Dose Intensive Chemotherapy

W. Jusko, M. Wetzler, W. Krzyzanski, 2002, Journal of clinical pharmacology.

Characterization of Pharmacodynamic Recession Slopes for Direct and Indirect Response Models

W. Jusko, W. Krzyzanski, 1998, Journal of Pharmacokinetics and Biopharmaceutics.

Ordinary differential equation approximation of gamma distributed delay model

W. Krzyzanski, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Indirect pharmacodynamic models for responses with circadian removal

W. Jusko, Vivaswath S. Ayyar, W. Krzyzanski, 2019, Journal of Pharmacokinetics and Pharmacodynamics.